Write CSS OR LESS and hit save.
develop transformative medicines for patients with incurable blood We use cookies to give you a better experience on genengnews.com. Celgene said it expects regulatory approval for JCAR017 in the US in 2019 with potential global peak sales of approximately $3 billion. The buyer said it has not changed its previously-disclosed 2020 financial targets of total net product sales of $19 billion to $20 billion, and adjusted EPS greater than $12.50. SUMMIT, N.J. & SEATTLE–(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno.
Celgene has agreed to acquire Juno Therapeutics, a Seattle, Washington biopharmaceutical company developing cancer immunotherapies, for approximately $9 billion.
evaluating multiple targets and cancer indications.
Celgene will also gain additional cellular therapy assets in proof-of-concept trials for hematologic malignancies and solid tumors.The acquisition will provide Celgene a scientific platform that complements Celgene’s position in hematology and oncology as well as scalable manufacturing capabilities.
The transaction is anticipated to close in Q1:18.Celgene expects to fund the transaction through a combination of existing cash and new debt. According to The Wall Street Journal, Celgene is thinking about acquiring Juno Therapeutics outright. lymphoma program, JCAR017 (lisocabtagene maraleucel; liso-cel)
Yet Celgene also views the Juno acquisition as an avenue toward a greater presence in cancer therapeutics. Acquisition Will Add Novel Scientific Platform and Manufacturing Expertise to Celgene’s Research and Operational Capabilities. At ASH, Juno announced a three-month overall response rate (ORR) of 74% (14/19) and a three-month complete response (CR) rate of 68% (13/19). Morgan Securities LLC is acting as financial advisor to Celgene on the transaction.
The conference call will be available by webcast on the Investor Relations page of Celgene’s website, You are now leaving www.CELGENE.com, a website provided by Celgene. Celgene will acquire all the outstanding shares of common stock of Juno through a tender offer for $87 per share in cash, or an aggregate of approximately $9 billion, net of … CTRL + SPACE for auto-complete.Celgene to Acquire Juno for $9B, Expanding CAR-T, TCR PresenceCEO of Loncar Investments, who tracks developments in cancer immunotherapy.
In their announcement today, the companies said JCAR017 is expected to add approximately $3 billion in peak sales—based on the expectation of winning FDA approval in 2019—and “significantly” strengthen Celgene’s lymphoma portfolio.
JCAR017 is Expected to be a Significant Growth Driver Beyond 2020 with Potential Global Peak Sales of Approximately $3B. towards a common goal of finding cures by creating cell therapies that In collaboration with Juno's team in
JCAR017 is a defined composition CD19-directed CAR T cell product candidate using a 4-1BB costimulatory domain, and is also known as lisocabtagene maraleucel (liso-cel). The boards of both companies have approved the transaction, which is expected to close in the first quarter. Celgene Corp. celg on Monday said it's reached a deal to buy Juno Therapeutics Inc., a biotech company developing cancer treatments, for $9 billion, or $87 a share in cash. Under terms of their agreement, Celgene agreed to acquire all outstanding common shares of Juno through a tender offer for $87 per share in cash, net of cash and marketable securities acquired, and the approximately 9.7% of Juno shares already owned by Celgene. ET.
Across doses, 80% (16/20) of core-group patients with CR at 3 months stayed in CR at 6 months, and 92% (11/12) of patients in response at 6 months remained in response as of the data cutoff date.
“I think they are making a mistake by relying on JCAR-017,” Loncar
Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene (approximately 9.7% of outstanding shares).
In their announcement today, Celgene and Juno cited Celgene’s plans to advance several Juno CAR-T cellular immunotherapies, the furthest along of which is JCAR017, now in a pivotal program for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). hematology and oncology. By continuing to use our site, you are agreeing to the use of cookies as set in our